Search Results for "Vical Herpes Vaccine 2012"
Original Source: Genital human papilloma virus HPV Vaccines
Genital human papilloma virus is one of the most common sexually transmitted infections (STI). Two vaccines are commercially available to protect females against the types of HPV that cause most cervical cancers. One of these vaccines also protects against...
Matching Channels
Matching News
Glaxo genital herpes vaccine flops but Agenus a buy in vaccine space
By Rex Graham A Glaxo Smith Kline (Nasdaq: GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc...
Vical's Herpes Vaccine: New Lab Results Confirm Move To The Clinic
By Theodore Cohen:In August 2011 and February 2012 I presented detailed overviews of Vical Incorporated's (VICL) herpes simplex virus type 2 or HSV-2 vaccine. Of the two serotypes identified, HSV-1 an...
Glaxo's Genital Herpes Vaccine Flops But Genocea's Next-Generation Approach Makes It A Buy
By Rex Graham:A GlaxoSmithKline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but "next generation" genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vica...
Vical Announces Publication of Herpes Simplex Vaccine Guinea Pig Study Data
SAN DIEGO, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced the publication of a new article1 in the journal Vaccine detailing results from the company's completed gu...
Vical licenses vaccine technology to Cyvax
Vical Inc. said Wednesday that it licensed its Vaxfectin technology, which is designed to make vaccines more effective, to a company that intends to use it in malaria vaccines.Vical said privately he...
Vical rises on Vaxfectin license agreement
Shares of Vical Inc. rose Thursday after the company said it licensed vaccine and immunization technology to drugmaker Bristol-Myers Squibb Co.Vical said Bristol-Myers is receiving a worldwide non-ex...
[Bristol] to produce antibodies using [Vical]’s platform
[Bristol-Myers Squibb Co.] has received nonexclusive global rights to DNA drug delivery company [Vical Inc.]’s DNA immunization technology to produce antibodies for human therapeutic use. Vical wil...
While the vaccine for Herpes Zoster is a safe and effective preventive measure for reducing the overall burden and severity of HZ, the skin test [...]
Matching PubMed Articles
Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
Approximately 1 million episodes of herpes zoster occur annually in the United States. Although prelicensure data provided evidence that herpes zoster vaccine works in a select study population under...
Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administ...
Neurologic complications from varicella zoster virus (VZV) reactivation are rare. In this article, we describe a previously immunized child who developed herpes zoster with meningitis. Vaccine strain...
Estimating the age-specific duration of herpes zoster vaccine protection: A matter of model choice?
The estimation of herpes zoster (HZ) vaccine efficacy by time since vaccination and age at vaccination is crucial to assess the effectiveness and cost-effectiveness of HZ vaccination. Published estima...
Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
To assess the cost-effectiveness of vaccinating all or subgroups of adults aged 60 to 85 years against herpes zoster.
